End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.75 CNY | -5.06% | -8.76% | -53.76% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.36 for the current year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-53.76% | 711M | C- | ||
+39.50% | 6.11B | B- | ||
+5.32% | 3.28B | C | ||
-18.39% | 2.86B | B- | ||
-6.41% | 2.41B | - | D+ | |
+42.43% | 1.9B | - | ||
-14.15% | 1.56B | - | - | |
-4.27% | 1.57B | - | - | |
+38.37% | 1.43B | - | ||
-15.57% | 1.48B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 002424 Stock
- Ratings Guizhou Bailing Group Pharmaceutical Co., Ltd.